Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 12/20 | 0.44 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | MAP3K7 | O43318 | 4/20 | 0.39 |
| ▸ | TAB1 | Q15750 | 4/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16703155 | 0.93 | JAK1 (0.43) | HTR6JAK1HTR2AHTR7PDPK1 | |
| SCHEMBL16697789 | 0.91 | MAP3K7 (0.49) | HTR6MAP3K7TAB1 | |
| SCHEMBL16698270 | 0.91 | JAK1 (0.44) | HTR6JAK1HTR2AHTR7PDPK1 | |
| SCHEMBL16698402 | 0.91 | JAK1 (0.42) | HTR6JAK1HTR2AHTR7PDPK1 | |
| SCHEMBL16697643 | 0.88 | HTR6 (0.47) | HTR6JAK1HTR2AHTR7PDPK1 | |
| SCHEMBL16698293 | 0.86 | HTR6 (0.42) | HTR6JAK1HTR2AHTR7PDPK1 | |
| SCHEMBL16698162 | 0.86 | HTR6 (0.42) | HTR6JAK1HTR2AHTR7PDPK1 | |
| SCHEMBL16698062 | 0.86 | HTR6 (0.42) | HTR6JAK1HTR2AHTR7PDPK1 | |
| SCHEMBL16703458 | 0.85 | JAK1 (0.44) | HTR6JAK1HTR2AHTR7PDPK1 | |
| SCHEMBL16697712 | 0.85 | DYRK1A (0.44) | HTR6PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160263087-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2016-09-15 | — | — | US | disclosed |
| US-20150328228-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-11-19 | — | — | US | disclosed |
| US-9126984-B2 | 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use | ITEOS THERAPEUTICS SA (BE) | 2015-09-08 | — | — | US | disclosed |
| US-20150133422-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS SA (BE) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133422-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, IDO2 | HTR6 101/4885JAK1 314/4885HTR2A 79/4885 |
| US-20160263087-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, TPH1 | HTR6 84/4885JAK1 513/4885HTR2A 94/4885 |
| US-20150328228-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, IDO2 | HTR6 144/4885JAK1 408/4885HTR2A 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.